Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1993 1
1995 1
2001 1
2004 1
2006 1
2009 1
2010 2
2011 4
2012 1
2013 2
2014 1
2015 3
2016 2
2020 3
2021 1
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Retinitis pigmentosa 51"
Page 1
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Haqq AM, et al. Lancet Diabetes Endocrinol. 2022 Dec;10(12):859-868. doi: 10.1016/S2213-8587(22)00277-7. Epub 2022 Nov 7. Lancet Diabetes Endocrinol. 2022. PMID: 36356613 Free PMC article. Clinical Trial.
We aimed to evaluate the effect of setmelanotide on bodyweight in these patients. METHODS: This multicentre, randomised, 14-week double-blind, placebo-controlled, phase 3 trial followed by a 52-week open-label period, was performed at 12 sites (hospitals, clinics, a …
We aimed to evaluate the effect of setmelanotide on bodyweight in these patients. METHODS: This multicentre, randomised, 14-week doub …
NGF and therapeutic prospective: what have we learned from the NGF transgenic models?
Aloe L, Rocco ML. Aloe L, et al. Ann Ist Super Sanita. 2015;51(1):5-10. doi: 10.4415/ANN_15_01_03. Ann Ist Super Sanita. 2015. PMID: 25857378 Free article. Review.
It has been shown that topical nerve growth factor (NGF) administration induces healing action on human cutaneous, corneal and pressure ulcers, glaucoma, maculopathy and retinitis pigmentosa suggesting a therapeutic potential of NGF in human ophthalmology and cutane …
It has been shown that topical nerve growth factor (NGF) administration induces healing action on human cutaneous, corneal and pressure ulce …
Corneal characteristics in patients with retinitis pigmentosa.
Zeki Fikret C, Ucgun NI, Karaca EE, Evren Kemer O. Zeki Fikret C, et al. Photodiagnosis Photodyn Ther. 2023 Jun;42:103554. doi: 10.1016/j.pdpdt.2023.103554. Epub 2023 Apr 6. Photodiagnosis Photodyn Ther. 2023. PMID: 37030435
BACKGROUND: To evaluate corneal topography and specular microscopic findings in patients with retinitis pigmentosa. METHODS: One hundred and two eyes of 51 patients with retinitis pigmentosa and 60 eyes of 30 healty subjects were included in our …
BACKGROUND: To evaluate corneal topography and specular microscopic findings in patients with retinitis pigmentosa. METHODS: O …
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa.
Schwartz SG, Wang X, Chavis P, Kuriyan AE, Abariga SA. Schwartz SG, et al. Cochrane Database Syst Rev. 2020 Jun 18;6(6):CD008428. doi: 10.1002/14651858.CD008428.pub3. Cochrane Database Syst Rev. 2020. PMID: 32573764 Free PMC article.
BACKGROUND: Retinitis pigmentosa (RP) comprises a group of hereditary eye diseases characterized by progressive degeneration of retinal photoreceptors. ...The certainty of the evidence was very low. One trial (51 participants) that assessed optical coh …
BACKGROUND: Retinitis pigmentosa (RP) comprises a group of hereditary eye diseases characterized by progressive degeneration o …
Safety and Efficacy of Adeno-Associated Viral Gene Therapy in Patients With Retinal Degeneration: A Systematic Review and Meta-Analysis.
Sobh M, Lagali PS, Ghiasi M, Montroy J, Dollin M, Hurley B, Leonard BC, Dimopoulos I, Lafreniere M, Fergusson DA, Lalu MM, Tsilfidis C. Sobh M, et al. Transl Vis Sci Technol. 2023 Nov 1;12(11):24. doi: 10.1167/tvst.12.11.24. Transl Vis Sci Technol. 2023. PMID: 37982768 Free PMC article.
Of these, 80 publications met eligibility criteria, representing 28 registered clinical trials and 5 postmarket surveillance studies involving AAV gene therapy for Leber congenital amaurosis (LCA), choroideremia, Leber hereditary optic neuropathy (LHON), age-related macula …
Of these, 80 publications met eligibility criteria, representing 28 registered clinical trials and 5 postmarket surveillance studies …
MRI of rod cell compartment-specific function in disease and treatment in vivo.
Berkowitz BA, Bissig D, Roberts R. Berkowitz BA, et al. Prog Retin Eye Res. 2016 Mar;51:90-106. doi: 10.1016/j.preteyeres.2015.09.001. Epub 2015 Sep 4. Prog Retin Eye Res. 2016. PMID: 26344734 Free PMC article. Review.
Rod cell oxidative stress is a major pathogenic factor in retinal disease, such as diabetic retinopathy (DR) and retinitis pigmentosa (RP). Personalized, non-destructive, and targeted treatment for these diseases remains elusive since current imaging methods cannot …
Rod cell oxidative stress is a major pathogenic factor in retinal disease, such as diabetic retinopathy (DR) and retinitis pigment …
Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome.
Aleman TS, Duncan JL, Bieber ML, de Castro E, Marks DA, Gardner LM, Steinberg JD, Cideciyan AV, Maguire MG, Jacobson SG. Aleman TS, et al. Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1873-81. Invest Ophthalmol Vis Sci. 2001. PMID: 11431456
PURPOSE: To determine macular pigment (MP) in patients with inherited retinal degeneration and the response of MP and vision to supplementation of lutein. METHODS: Patients with retinitis pigmentosa (RP) or Usher syndrome and normal subjects had MP optical density p …
PURPOSE: To determine macular pigment (MP) in patients with inherited retinal degeneration and the response of MP and vision to supplementat …
Application of intravitreal aflibercept to treat bilateral exudative retinal detachment secondary to retinitis pigmentosa: Case report and review of literature.
Kao CC, Chen KJ, Cheng KC. Kao CC, et al. Medicine (Baltimore). 2023 Dec 22;102(51):e36589. doi: 10.1097/MD.0000000000036589. Medicine (Baltimore). 2023. PMID: 38134121 Free PMC article. Review.
RATIONALE: Exudative retinal detachment with macular edema is one of the complications of retinitis pigmentosa (RP). In this report, we present a case who treated with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in RP-related exudat …
RATIONALE: Exudative retinal detachment with macular edema is one of the complications of retinitis pigmentosa (RP). In this r …
Locus-Level Changes in Macular Sensitivity in Patients with Retinitis Pigmentosa Treated with Oral N-acetylcysteine.
Kong X, Hafiz G, Wehling D, Akhlaq A, Campochiaro PA. Kong X, et al. Am J Ophthalmol. 2021 Jan;221:105-114. doi: 10.1016/j.ajo.2020.08.002. Epub 2020 Aug 11. Am J Ophthalmol. 2021. PMID: 32795434 Free PMC article. Clinical Trial.
PURPOSE: To identify characteristics of loci associated with locus-level sensitivity loss or improvement during treatment with N-acetylcysteine (NAC) in retinitis pigmentosa (RP). DESIGN: Retrospective analysis of prospectively collected data in the FIGHT RP clin …
PURPOSE: To identify characteristics of loci associated with locus-level sensitivity loss or improvement during treatment with N-acetylcyste …
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial.
Fischer MD, Michalakis S, Wilhelm B, Zobor D, Muehlfriedel R, Kohl S, Weisschuh N, Ochakovski GA, Klein R, Schoen C, Sothilingam V, Garcia-Garrido M, Kuehlewein L, Kahle N, Werner A, Dauletbekov D, Paquet-Durand F, Tsang S, Martus P, Peters T, Seeliger M, Bartz-Schmidt KU, Ueffing M, Zrenner E, Biel M, Wissinger B. Fischer MD, et al. JAMA Ophthalmol. 2020 Jun 1;138(6):643-651. doi: 10.1001/jamaophthalmol.2020.1032. JAMA Ophthalmol. 2020. PMID: 32352493 Free PMC article. Clinical Trial.
MAIN OUTCOMES AND MEASURES: Safety as the primary end point was assessed by clinical examination of ocular inflammation. Systemic safety was assessed by vital signs, routine clinical chemistry testing, and full and differential blood cell counts. ...TRIAL REG …
MAIN OUTCOMES AND MEASURES: Safety as the primary end point was assessed by clinical examination of ocular inflammation. Systemic saf …
28 results